DOI 10.15372/SSMJ20180304
INVESTIGATION OF THE ANTIVIRAL ACTIVITY OF AN ORAL DRUG PREPARATION BASED ON IMMOBILIZED INTERFERON λ-1
Author Affiliations1Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52; «Scientific Future Management» company 630559, Novosibirsk region, settlement Koltsovo, Tecnoparkovaya str., 10
2Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52; «Scientific Future Management» company 630559, Novosibirsk region, settlement Koltsovo, Tecnoparkovaya str., 10
3State Research Center of Virology and Biotechnology «Vector» 630559, Novosibirsk region, settlement Koltsovo
4Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
5Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
Abstract
Despite the success in developing direct-acting antiviral drugs, in routine clinical practice the use of interferons remains relevant. Parenteral administration of interferons is accompanied by systemic side effects and presents significant inconveniences for patients. A drug based on interferon λ-1, which has high enteric bioavailability and ensures its high concentration in the liver, is promising for the effective treatment of hepatotropic viruses. The aim of the investigation was to study the antiviral activity of an oral medicine based on interferon λ-1 immobilized on polyethylene glycol-1500 by electron-beam synthesis technology. Materials and methods: Real time PCR, Western blot and immunohistochemical method were used to study antiviral activity of tested medicine against hepatitis C virus. Results and discussion: The tested medicine retains antiviral activity against hepatitis C virus. All obtained results are consistent with each other. A 50 % inhibitory dose is in the range of 0.008–0.08 ng/ml. Conclusion: IFN λ-1 immobilized on polyethylene glycol with the help of radiation synthesis technology can be considered as a prototype of an oral drug for the treatment of viral hepatitis, in particular hepatitis C.
Key words
ReferencesArtamonov A.A., Bekarev A.V., Vereschagin E.I. Method for immobilising biologically active substances on polymer carriers (variants) and conjugates produced by said method. Patent № 2409669 RF; published 13.05.2014. [In Russian].
Kinsht D.N., Madonov P.G., Svyatchenko V.A., Ternovoy V.А. Experimental substantiation of application of pegylated interferon α-2b oral formulation for therapy of enteroviral infection. Sibirskiy nauchnyy medtsinskiy zhurnal = Siberian Scientific Medical Journal. 2017. . 37. (3). 11-16. [In Russian].
Madonov P.G., Ershov K.I., Dubrovin A.V., Zapolotskiy E.N., Miroshnikov P.N., Shilova M.A., Kinsht D.N. Electron-beam modification of the protein nature of drugs to improve their pharmacological properties. Meditsina i obrazovanie v Sibiri = Medicine and Education in Siberia. 2013. (4). http://ngmu.ru/cozo/mos/article/text_full.php?id=1115). – Date of the application: 08.11.2017. [In Russian].
Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., Rice C.M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006. 131. 1887-1898.
Veronese F.M. Pasut G. Protein PEGylation. Long acting injections and implants. Eds. J.C. Wright, D.J. Burgess. N.Y.; Dordrecht; Heidelberg; L.: Springer, 2012. 295-314.
About Authors (Correspondence):
Kinsht D.N. – candidate of medical sciences, associate professor of the chair for pharmacology, clinical pharmacology and evidentiary medicine, е-mail: kinsht@scpb.ru
Full Text
Received: 27/06/2018
Accepted: 27/06/2018
